- Home
- KPRX vs MITQ Comparison
KPRX vs MITQ Comparison
Compare KPRX & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- MITQ
- Stock Information
- Founded
- KPRX 1998
- MITQ N/A
- Country
- KPRX United States
- MITQ United States
- Employees
- KPRX N/A
- MITQ N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MITQ Telecommunications Equipment
- Sector
- KPRX Health Care
- MITQ Telecommunications
- Exchange
- KPRX Nasdaq
- MITQ Nasdaq
- Market Cap
- KPRX 8.7M
- MITQ 7.6M
- IPO Year
- KPRX N/A
- MITQ 2021
- Fundamental
- Price
- KPRX $2.71
- MITQ $0.75
- Analyst Decision
- KPRX Strong Buy
- MITQ
- Analyst Count
- KPRX 1
- MITQ 0
- Target Price
- KPRX $10.00
- MITQ N/A
- AVG Volume (30 Days)
- KPRX 80.3K
- MITQ 47.9K
- Earning Date
- KPRX 08-08-2025
- MITQ 09-25-2025
- Dividend Yield
- KPRX N/A
- MITQ N/A
- EPS Growth
- KPRX N/A
- MITQ N/A
- EPS
- KPRX N/A
- MITQ N/A
- Revenue
- KPRX N/A
- MITQ $18,613,000.00
- Revenue This Year
- KPRX N/A
- MITQ N/A
- Revenue Next Year
- KPRX N/A
- MITQ N/A
- P/E Ratio
- KPRX N/A
- MITQ N/A
- Revenue Growth
- KPRX N/A
- MITQ N/A
- 52 Week Low
- KPRX $2.25
- MITQ $0.50
- 52 Week High
- KPRX $4.18
- MITQ $1.55
- Technical
- Relative Strength Index (RSI)
- KPRX 48.49
- MITQ 54.72
- Support Level
- KPRX $2.67
- MITQ $0.73
- Resistance Level
- KPRX $2.90
- MITQ $0.78
- Average True Range (ATR)
- KPRX 0.14
- MITQ 0.04
- MACD
- KPRX 0.01
- MITQ 0.00
- Stochastic Oscillator
- KPRX 39.13
- MITQ 66.67
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.